Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ALPN

ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

64.97USD Market Closed

Market Summary

ALPN
USD64.97
Market Closed

ALPN Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

ALPN Stock Price

View Fullscreen

ALPN RSI Chart

ALPN Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-120.99

Price/Sales (Trailing)

78.85

EV/EBITDA

-140.57

Price/Free Cashflow

-55.05

ALPN Price/Sales (Trailing)

ALPN Profitability

EBT Margin

-56.76%

Return on Equity

-11.07%

Return on Assets

-9.86%

Free Cashflow Yield

-1.82%

ALPN Fundamentals

ALPN Revenue

Revenue (TTM)

56.5M

Rev. Growth (Yr)

-25.09%

Rev. Growth (Qtr)

-77.21%

ALPN Earnings

Earnings (TTM)

-36.8M

Earnings Growth (Yr)

-35.07%

Earnings Growth (Qtr)

-400.64%

Breaking Down ALPN Revenue

Last 7 days

0.1%

Last 30 days

0.8%

Last 90 days

107.8%

Trailing 12 Months

655.5%

How does ALPN drawdown profile look like?

ALPN Financial Health

Current Ratio

9.56

ALPN Investor Care

Shares Dilution (1Y)

43.01%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202456.5M000
202325.8M29.1M30.8M58.9M
202233.9M32.0M31.8M30.1M
202111.4M18.0M24.6M23.4M
20202.8M3.0M4.6M9.3M
201901.1M1.4M1.7M
20181.5M1.1M910.2K705.0K
20172.6M2.3M2.0M1.7M
2016001.7M3.0M
2015000492.0K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alpine Immune Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 20, 2024
peetz christopher
back to issuer
-
-
-1,900
-
May 20, 2024
gold mitchell
back to issuer
-
-
-109,245
executive chairman and ceo
May 20, 2024
rickey james paul
back to issuer
-
-
-57,961
see remarks
May 20, 2024
durand remy
back to issuer
-
-
-266,784
chief business officer
May 20, 2024
conway robert e
back to issuer
-
-
-50,000
-
May 20, 2024
fuhs ulrich martin
back to issuer
-
-
-60,240
chief accounting officer

1–10 of 50

Which funds bought or sold ALPN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 28, 2024
Boston Partners
new
-
915,720
915,720
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
233,876
233,876
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
87.86
372,653
500,653
0.06%
May 20, 2024
Virtu Financial LLC
new
-
587,000
587,000
0.04%
May 17, 2024
Ikarian Capital, LLC
reduced
-46.36
1,073,560
10,360,500
1.14%
May 17, 2024
Artal Group S.A.
added
699
15,118,300
16,085,300
0.41%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
5.33
707,137
1,301,100
-%
May 16, 2024
JANE STREET GROUP, LLC
added
155
5,709,710
7,033,480
-%
May 16, 2024
AWM Investment Company, Inc.
unchanged
-
823,200
1,585,600
0.21%
May 15, 2024
Voya Investment Management LLC
added
64.52
602,479
851,269
-%

1–10 of 45

Are Funds Buying or Selling ALPN?

Are funds buying ALPN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALPN
No. of Funds

Unveiling Alpine Immune Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 21, 2024
frazier life sciences viii, l.p.
0.0%
0
SC 13D/A
May 21, 2024
decheng capital china life sciences usd fund iii, l.p.
0.0%
0
SC 13D/A
Apr 30, 2024
decheng capital china life sciences usd fund iii, l.p.
10.0%
6,582,380
SC 13D/A
Apr 29, 2024
frazier life sciences viii, l.p.
4.3%
2,829,347
SC 13D/A
Mar 07, 2024
blackrock inc.
4.6%
3,026,330
SC 13G/A
Feb 14, 2024
omega fund vi, l.p.
0.0%
0
SC 13G/A
Feb 14, 2024
paradigm biocapital advisors lp
5.5%
3,176,743
SC 13G/A
Feb 14, 2024
lynx1 capital management lp
6.6%
3,813,926
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
4.39%
2,550,000
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.99%
5,903,234
SC 13G/A

Recent SEC filings of Alpine Immune Sciences Inc

View All Filings
Date Filed Form Type Document
May 30, 2024
15-12G
15-12G
May 23, 2024
EFFECT
EFFECT
May 23, 2024
EFFECT
EFFECT
May 21, 2024
SC 13D/A
13D - Major Acquisition
May 21, 2024
SC 13D/A
13D - Major Acquisition
May 20, 2024
POS AM
POS AM
May 20, 2024
S-8 POS
Employee Benefits Plan
May 20, 2024
POS AM
POS AM
May 20, 2024
S-8 POS
Employee Benefits Plan
May 20, 2024
S-8 POS
Employee Benefits Plan

Peers (Alternatives to Alpine Immune Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Alpine Immune Sciences Inc News

Latest updates
Defense World10 Jun 202403:24 pm

Alpine Immune Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue-77.2%7,032,00030,853,00010,043,0008,593,0009,387,0002,776,0008,367,0005,292,00013,629,0004,530,0008,516,0007,193,0003,204,0005,643,0001,913,000688,0001,091,000884,000289,000567,000448,000
Operating Expenses1.4%29,728,00029,306,00024,593,00024,248,00024,979,00023,145,00022,199,00021,781,00021,086,00019,906,00021,779,00017,924,00013,693,00012,104,0008,884,00010,440,0006,656,0007,901,00011,999,00012,719,00011,445,000
  S&GA Expenses14.1%7,271,0006,374,0005,443,0005,007,0005,398,0004,389,0004,610,0004,194,0004,775,0004,544,0003,470,0003,290,0003,256,0003,049,0002,728,0003,344,0001,778,0002,102,0002,467,0002,553,0002,514,000
  R&D Expenses-2.1%22,457,00022,932,00019,150,00019,241,00019,581,00018,756,00017,589,00017,587,00016,311,00015,362,00018,309,00014,634,00010,437,0009,055,0006,156,0007,096,0004,878,0005,799,0009,532,00010,166,0008,931,000
EBITDA Margin-4.4%-0.56-0.53-1.81-1.96-2.33-1.81-1.62-1.61-1.36-2.09-1.62-1.81---------
Interest Expenses----28,00070,00087,000105,000130,000154,000178,000203,000218,000217,000215,000214,000226,000120,000141,00066,00061,00076,000
Income Taxes-100.0%-103,000---548,000-1,778,0004,000-298,00080,000131,000----6,000-----61,000
Earnings Before Taxes-100.0%-6,063,000-11,722,000-13,156,000-13,266,000-18,316,000-13,273,000-16,320,000-7,523,000-15,465,000-13,414,000-10,898,000-10,643,000-6,342,000-6,137,000-9,934,000--6,140,000-11,475,000-11,856,000-11,196,000
EBT Margin-4.2%-0.57-0.54-1.83-1.99-2.37-1.84-1.65-1.65-1.40-2.15-1.68-1.89---------
Net Income-400.6%-17,918,0005,960,000-11,722,000-13,156,000-13,266,000-18,864,000-13,273,000-18,098,000-7,527,000-15,167,000-13,494,000-11,029,000-10,643,000-6,342,000-6,137,000-9,928,000-5,533,000-6,140,000-11,475,000-11,856,000-11,135,000
Net Income Margin-19.2%-0.65-0.55-1.85-2.01-2.46-1.92-1.70-1.70-1.39-2.15-1.69-1.90---------
Free Cashflow-45.2%-27,709,000-19,085,000-15,799,000-18,370,000-26,245,000-16,902,000-16,403,000-16,284,0005,423,000-14,778,00030,134,000-14,712,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.6%37438024125326228729221623425623316013014415410350.0054.0065.0070.0067.00
  Current Assets-6.6%30833019720719924125317217619218414010010714391.0038.0042.0052.0057.0065.00
    Cash Equivalents-24.8%33.0044.0019.0034.0015.0014.0012725.0035.0068.0076.0019.0013.0035.0014188.0025.0017.0018.0016.0042.00
  Net PPE-8.6%1.001.002.002.002.002.002.002.002.002.001.002.002.002.002.002.002.002.001.001.001.00
Liabilities-21.1%41.0052.0079.0083.0093.0010711011611913511111677.0082.0087.0086.0025.0025.0030.0025.0011.00
  Current Liabilities-23.2%32.0042.0052.0053.0057.0058.0068.0063.0068.0070.0064.0060.0043.0041.0036.0028.005.009.0014.0013.009.00
  Long Term Debt--------1.002.003.005.006.006.008.009.0010.008.005.005.001.002.00
    LT Debt, Current-----2.003.005.005.005.005.005.005.004.003.001.000.002.000.00-2.002.00
    LT Debt, Non Current--------1.002.003.005.006.006.008.009.0010.008.005.005.001.002.00
Shareholder's Equity1.5%33332816216917017918210011512112344.0053.0062.0067.0016.0025.0029.0035.0045.0057.00
  Retained Earnings-7.0%-274-256-262-250-237-223-205-191-173-166-151-137-126-115-109-103-93.46-87.93-81.79-70.31-58.45
  Additional Paid-In Capital4.0%607584424420407404389293290287274181180178177120118117117116115
Shares Outstanding8.6%66.0060.0049.0049.0048.0046.0032.0030.0030.0025.0024.0024.00---------
Float----349---132---105---50.00---21.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-46.0%-27,690-18,971-15,798-18,091-26,152-16,786-16,348-16,0695,449-14,72930,134-14,682-15,971-9,349-5,39254,519-9,694-5,671-10,575-7,877-11,223
  Share Based Compensation42.3%3,9892,8032,6542,6212,5522,4692,5552,3352,2891,4601,6381,5451,5979499731,232986780825682754
Cashflow From Investing97.7%-2,562-112,702-53529,32828,350-107,89925,7906,564-37,803-4,285-62,51520,866-6,546-96,8491,8439,05713,1304,38810,863-17,58719,099
Cashflow From Financing-87.6%19,351156,6101,2018,398-1,08711,54392,816-1,020-65010,87389,6809.00202-11.0056,3902.005,000-1,646-50923,118
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALPN Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Collaboration [Member]Collaboration [Member]
Collaboration revenue$ 7,032$ 9,387
Operating expenses:  
Research and development22,45719,581
General and administrative7,2715,398
Total operating expenses29,72824,979
Loss from operations(22,696)(15,592)
Other income (expense):  
Interest income4,7812,418
Interest expense0(70)
Other, net(3)(22)
Net loss(17,918)(13,266)
Comprehensive income (loss):  
Unrealized (loss) gain on investments(551)745
Unrealized loss on foreign currency translation(109)(31)
Comprehensive loss$ (18,578)$ (12,552)
Weighted-average shares used to compute basic net loss per share (in shares)64,033,01847,568,149
Weighted-average shares used to compute diluted net loss per share (in shares)64,033,01847,568,149
Basic net loss per share (in dollars per share)$ (0.28)$ (0.28)
Diluted net loss per share (in dollars per share)$ (0.28)$ (0.28)

ALPN Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 33,015$ 43,921
Short-term investments272,646283,491
Accounts receivable42167
Prepaid expenses and other current assets2,5482,455
Total current assets308,251330,034
Restricted cash, noncurrent269268
Property and equipment, net1,3561,484
Operating lease, right-of-use asset7,3177,510
Long-term investments56,45340,556
Total assets373,646379,852
Current liabilities:  
Accounts payable4,1703,593
Accrued liabilities16,89121,187
Deferred revenue, current10,22716,288
Operating lease liability, current950912
Total current liabilities32,23841,980
Deferred revenue, noncurrent0929
Operating lease liability, noncurrent8,7059,002
Total liabilities40,94351,911
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.001 par value per share; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 65,552,322 and 60,347,457 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively6660
Additional paid-in capital606,963583,629
Accumulated other comprehensive (loss) income(263)397
Accumulated deficit(274,063)(256,145)
Total stockholders’ equity332,703327,941
Total liabilities and stockholders’ equity$ 373,646$ 379,852
ALPN
Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEalpineimmunesciences.com
 INDUSTRYBiotechnology
 EMPLOYEES126

Alpine Immune Sciences Inc Frequently Asked Questions


What is the ticker symbol for Alpine Immune Sciences Inc? What does ALPN stand for in stocks?

ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alpine Immune Sciences Inc (ALPN)?

As of Mon May 20 2024, market cap of Alpine Immune Sciences Inc is 4.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers. The fair value of Alpine Immune Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alpine Immune Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alpine Immune Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALPN is over valued or under valued. Whether Alpine Immune Sciences Inc is cheap or expensive depends on the assumptions which impact Alpine Immune Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALPN.

What is Alpine Immune Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 20 2024, ALPN's PE ratio (Price to Earnings) is -120.99 and Price to Sales (PS) ratio is 78.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALPN PE ratio will change depending on the future growth rate expectations of investors.